Cargando…
Oncogenic Mutations Regulate Tumor Microenvironment through Induction of Growth Factors and Angiogenic Mediators
Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared to wild-type HER2, mutant HER2 shows constitutively activate kinase activity and increased oncogenicity. Cells transformed by mutant HER2 are resistant to EGFR tyrosine kinase inhibitor...
Autores principales: | Wang, Shizhen Emily, Yu, Yang, Criswell, Tracy L., DeBusk, Laura M., Lin, P. Charles, Zent, Roy, Johnson, David H., Ren, Xiubao, Arteaga, Carlos L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883631/ https://www.ncbi.nlm.nih.gov/pubmed/20383197 http://dx.doi.org/10.1038/onc.2010.112 |
Ejemplares similares
-
P02.194. Newly developed functional medicine program in diabetes: impact on clinical and patient reported outcomes - functional medicine and quality of life
por: Franic, D, et al.
Publicado: (2012) -
Heterozygous deficiency of δ-catenin impairs pathological angiogenesis
por: DeBusk, Laura M., et al.
Publicado: (2010) -
Heterozygous deficiency of δ-catenin impairs pathological angiogenesis
por: DeBusk, Laura M., et al.
Publicado: (2010) -
Heterozygous deficiency of δ-catenin impairs pathological angiogenesis
por: DeBusk, Laura M., et al.
Publicado: (2010) -
The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?
por: Zhang, Lin, et al.
Publicado: (2020)